Novacyt Sas · EURONEXT:ALNOV
Novacyt Sas — Novacyt — H1 2023 Earnings Presentation
19 slides from Novacyt Sas's earnings presentation, Sep 28, 2023
Slide 1: 2023 Interim Results
2023 Interim Results 28 September 2023 1
Slide 2: Disclaimer
Disclaimer The document attached hereto and the presentation of which it forms part (together the “Materials”) have been prepared by Novacyt S.A. (“Novacyt” or the “Company”). The Materials are confidential and personal to you and are furnished to you as background information to provide a basis for
Slide 3: Presenters
Presenters • Acting CEO since November 2022 • Appointed CFO of Novacyt in 2021 • Joined Novacyt in 2017 • Over 30 years in international manufacturing • Group Finance Director since February 2020 and industrial businesses in both consumer • Over 12 years in financial management at a and B2B globally
Slide 4: 2023 Unaudited Interim Results
2023 Unaudited Interim Results 4
Slide 5: Good strategic progress
Good strategic progress • Strategic acquisition of Yourgene • Instrument Sales posted 65% Health plc growth in Q2 versus Q1 • Exclusive agreement with • Launched Co-Prep extraction Eluceda to develop biosensor system technology Business Growth of Development Instrumentation • Completed development o
Slide 6: H1 2023 unaudited – Income statement
H1 2023 unaudited – Income statement Non-COVID-19 revenue continues to build Continuing Operations* H1 2023 H1 2022 £'000 £'000 • Group revenue for H1 2023 of £3.3m, (H1 2022: £16.5m), Revenue 3,339 16,508 due to expected decline in COVID-19-related sales. Gross profit 1,665 4,010 Gross profit % 50%
Slide 7: H1 2023 unaudited statement of financial position
H1 2023 unaudited statement of financial position Cash position remains strong Jun-23 Dec-22 Jun-23 Dec-22 £'000 £'000 £'000 £'000 Goodwill 6,482 6,646 Share capital and premium 54,601 54,633 Retained earnings and • Cash position at 30 June was £81.7m (FY 2022: Right-of-use assets 361 521 reserves 5
Slide 8: An Introduction to Yourgene
An Introduction to Yourgene 8
Slide 9: Yourgene: Integrated technologies and services for genomic medicine
Yourgene: Integrated technologies and services for genomic medicine • Develop, manufacture, and commercialise simple and Headquartered in accurate molecular diagnostic and screening solutions, Manchester, UK with offices in Singapore, the US and for reproductive health and precision medicine Canada
Slide 10: From a single product UK-based NIPT business to a leading international molecular diagnostics player
From a single product UK-based NIPT business to a leading international molecular diagnostics player • Acquisitions of Coastal Genomics, Ex5 Genomics and Adgenix DPNI • Rebranded to Yourgene Health plc • Addition of Ranger Technology • Premaitha lists on AIM • Thermo Fisher debt written-off for samp
Slide 11: Complementary suite of disruptive genomic products and services
Complementary suite of disruptive genomic products and services Genomic Technologies: In vitro diagnostic products Genomic Genomic • CE-marked IVD products for reproductive Technologies Services health, precision medicine and infectious Research: disease screening Target enrichment: Ranger® Technolo
Slide 12: Established international customer base
Established international customer base Direct sales force and UK service lab business Direct in key markets supported by distributor network ASIA EUROPE NORTH AMERICA Direct sales and Ranger business Direct in key markets supported by FY 2023 Sales distributor network AFRICA SOUTH AMERICA AUSTRALIA
Slide 13: Yourgene sales update
Yourgene sales update • Unaudited revenue for FY22/23 (April 2022 to March 2023) totals £19.1m (including £2.1m of COVID-19 sales) • Ranger® Technology product revenues have grown by over 100% to £2.3m • NIPT service and product revenues rose by over 20% to £8.6m • International sales increased by o
Slide 14: Combined Group
Combined Group A stronger global diagnostics business 14
Slide 15: Our combined strengths enhance our market position
Our combined strengths enhance our market position New expanded Group builds a stronger global diagnostics business with key strategic growth drivers: Expands our combined Enables further market Creates portfolio Creates a more robust and geographic commercial penetration and accelerates diversifica
Slide 16: Key objectives of integration over the next six months
Key objectives of integration over the next six months: 1 Secure and underpin core revenue growth in the Yourgene portfolio Secure / underpin core revenue growth in the Yourgene portfolio Leverage commercial expertise in combined business to accelerate growth of Novacyt portfolio and 2 identify syne
Slide 17: Focussed on delivering long-term sustainable growth
Focussed on delivering long-term sustainable growth • Acquisition of Yourgene Health was a significant strategic milestone • Integration plans underway to leverage combined capabilities to accelerate growth and drive efficiencies and synergies • Expect to share progress on Integration at the next Tr
Slide 18: NOVACYT
NOVACYT
Slide 19: Contact details
info@novacyt.com novacyt.com Novacyt Group (UK) York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG, UK T +44 (0)2380 748 830 19